Streetbeat News

Price Targets

BLK

BlackRock, Inc. (NYSE:BLK) reported strong Q3 earnings, with revenue and EPS beating expectations. Analysts from Morgan Stanley, Evercore ISI Group, and Barclays raised their price targets for BlackRock, reflecting positive sentiment. BlackRock's focus on private markets and infrastructure, especially AI innovation, is highlighted.

Portfolio Pulse from Avi Kapoor

October 14, 2024 | 6:21 pm

BK

Bank of New York Mellon (NYSE:BK) reported strong Q3 earnings, surpassing expectations with a 20% YoY increase in EPS and a 5% rise in revenue. Analysts have raised their price targets for BK, reflecting positive sentiment.

Portfolio Pulse from Avi Kapoor

October 14, 2024 | 6:15 pm

WFC

Wells Fargo reported better-than-expected Q3 earnings with a GAAP EPS of $1.42, surpassing the consensus of $1.28. Revenue slightly missed expectations, falling 2% to $20.37 billion. Analysts have adjusted their price targets for Wells Fargo, with Evercore ISI Group raising it to $71, Piper Sandler to $62, and RBC Capital maintaining it at $61. The company expects a 9% decline in net interest income for 2024.

Portfolio Pulse from Avi Kapoor

October 14, 2024 | 6:10 pm

JPM

JPMorgan Chase & Co. reported better-than-expected Q3 FY24 earnings, with revenue and EPS surpassing consensus estimates. Despite a slight decline in net income, the bank raised its FY24 net interest income forecast. Analysts revised their price targets for JPMorgan, with most increasing their targets.

Portfolio Pulse from Avi Kapoor

October 14, 2024 | 6:04 pm

VYX

Goldman Sachs analyst Will Nance has reinstated a Neutral rating on NCR Voyix (NYSE:VYX) and set a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 6:00 pm

IBTA

Goldman Sachs has upgraded Ibotta (NYSE:IBTA) from Neutral to Buy, maintaining the price target at $87.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 5:58 pm

HIMS

B of A Securities analyst Michael Cherny has maintained a Buy rating on Hims & Hers Health (NYSE:HIMS) and raised the price target from $20 to $23.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 5:52 pm

ALNY

B of A Securities has maintained a Buy rating on Alnylam Pharmaceuticals and raised its price target from $307 to $314.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 5:50 pm

C

USO

Citi maintains its baseline forecast for Brent oil prices at $74/barrel in Q4 2024 and $65/barrel in Q1 2025. The bank raises its bull case scenario for oil prices to $120/barrel for both quarters, while maintaining its bear scenario, which includes OPEC+ increasing production starting in December.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 5:49 pm

VRTX

B of A Securities has maintained its Buy rating on Vertex Pharmaceuticals but has slightly lowered the price target from $550 to $541.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 5:48 pm